This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Elderly patients

Elderly patients

Subgroup analyses of LUX-Lung 3 and LUX-Lung 6 patients showed that afatinib* treatment resulted in significant progression-free survival (PFS) benefit versus chemotherapy in patients aged ≥65 years in the overall study populations (median PFS in LUX-Lung 3: 11.3 vs 8.2 months, hazard ratio [HR]=0.64; 95% confidence interval [CI]: 0.39–1.03; median PFS in LUX-Lung 6: 13.7 vs 4.1 months; HR=0.16; 95% CI: 0.07–0.39). Afatinib was also associated with PFS benefit in patients in this age group whose tumours had common epidermal growth factor receptor

(EGFR) mutations (median PFS in LUX-Lung 3: 13.7 vs 8.2 months; HR=0.45; 95% CI: 0.26–0.78; median PFS in LUX-Lung 6: 13.7 vs 4.1 months; HR=0.15; 95% CI: 0.06–0.38).1 A significant increase in overall survival (OS) was also reported in elderly patients with del19 mutations in LUX-Lung 3 (median OS in this patient population: 41.5 vs 14.3 months; HR=0.39; 95% CI: 0.19–0.80).1 The safety profile of afatinib was generally similar across age groups, with a slightly higher incidence of Grade 3/4 treatment-related adverse events in elderly patients; however, this was also seen in the chemotherapy arm (cisplatin/pemetrexed in LUX-Lung 3 and cisplatin/gemcitabine in LUX-Lung 6).1

PFS outcomes in patients aged ≥65 years treated in LUX-Lung 3 and 6


CI, confidence interval; Cis, cisplatin; HR, hazard ratio; Pem, pemetrexed; PFS, progression-free survival.


CI, confidence interval; Cis, cisplatin; Gem, gemcitabine; HR, hazard ratio; PFS, progression-free survival.

In subgroup analyses of LUX-Lung 7, afatinib increased median PFS and OS versus gefitinib regardless of age group, although the difference between treatment arms did not reach significance in all age groups analysed.2

OS by age group in LUX-Lung 72


CI, confidence interval; HR, hazard ratio; OS, overall survival.

Did you find this information useful?



Wu YL, et al.  Clin Lung Cancer 2018;19(4):e465–79.


Park K, et al. J Thorac Oncol 2017;12(1):S1214.

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.


© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: January 2019